530306 PPM1D Phosphatase Inhibitor II, GSK2830371 - Calbiochem

530306
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability

      Overview

      Replacement Information

      Key Specifications Table

      Empirical Formula
      C₂₃H₂₉ClN₄O₂S

      Pricing & Availability

      Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
      5.30306.0001
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Glass bottle 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable, orally available pyridinylaminomethylthienylcarboxamide compound that acts as a potent, allosteric, non-competitive, and reversible inhibitor of wild-type p53-induced phosphatase (Wip1; IC50 = 6 nM for dephosphorylation of fluorescein diphosphate by Wip1 (2-240) and 13 nM for phospho-p38 MAP kinase (Thr180)). Does not affect the activity of 21 other phosphatases studied (IC50 ≥ 30 µM). Binds to the flap region in close proximity to Wip1 catalytic site and impairs ubiquitin-mediated degradation of Wip1. Co-treatment of cells with MG-132 (Cat. No. 474790) reverses the reduction in Wip1 levels in cells. Enhances phosphorylation of Chk2 (Thr68), p53 (Ser15), H2AX (Ser139), and ATM (Ser1981) and upregulates the levels of p21/WAF1 in various tumor cells. Shown to block the growth of hematopoietic tumor cell lines and Wip1-amplified breast tumor cells harboring wild-type TP53, but does not affect BT474 cells carrying mutant p53 and amplified Wip1. Due to its short half life and reversible action, a sustained inhibition is warranted to block tumor growth. Reduces the growth of DOHH2 lymphoma tumor xenografts in mice (~150 mg/kg, p.o. bid or tid).

          Please note that the molecular weight for this compound is batch-specific due to variable water content.
          Catalogue Number530306
          Brand Family Calbiochem®
          Synonyms(S)-5-((5-Chloro-2-methylpyridin-3-ylamino)methyl)-N-(3-cyclopentyl-1-(cyclopropylamino)-1-oxopropan-2-yl)thiophene-2-carboxamide, PP2Cδ Inhibitor II, Wip1 Inhibitor II, WT-53-Induced Phosphatase Inhibitor; GSK 2830371
          References
          ReferencesGilmartin, A.G., et al. 2014. Nature Chem. Biol. 10, 181.
          Product Information
          FormLight yellow powder
          Hill FormulaC₂₃H₂₉ClN₄O₂S
          Chemical formulaC₂₃H₂₉ClN₄O₂S
          ReversibleY
          Applications
          Biological Information
          Primary TargetWip1/PPM1D/PP2Cδ
          Primary Target IC<sub>50</sub>6 nM for dephosphorylation of fluorescein diphosphate by Wip1 (2-240) and 13 nM for phospho-p38 MAP kinase (Thr180)
          Purity≥97% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          PPM1D Phosphatase Inhibitor II, GSK2830371 - Calbiochem SDS

          Title

          Safety Data Sheet (SDS) 

          References

          Reference overview
          Gilmartin, A.G., et al. 2014. Nature Chem. Biol. 10, 181.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-June-2014 JSW
          Synonyms(S)-5-((5-Chloro-2-methylpyridin-3-ylamino)methyl)-N-(3-cyclopentyl-1-(cyclopropylamino)-1-oxopropan-2-yl)thiophene-2-carboxamide, PP2Cδ Inhibitor II, Wip1 Inhibitor II, WT-53-Induced Phosphatase Inhibitor; GSK 2830371
          DescriptionA cell-permeable pyridinylaminomethylthienylcarboxamide that acts as a potent inhibitor against wild-type p53-induced phosphatase Wip1/PPM1D/PP2Cδ activity (IC50/[wip1]/[substrate]= 6 nM/1 nM Wip1/50 µM FDP and 13 nM/15 nM Wip1/8 nM pT180 p38) via an allosteric interaction with the ′flap′ region outside the catalytic site in a reversible and substrate-noncompetitive manner, while exhibiting little potency toward yeast YopH and 22 other human phosphatases (IC50 >30 µM), including PPM1A/PP2Cα & PPM1K/PP2Cκ. Shown to increase cellular Wip1 substrates phosphorylation, including p53 (S15), Chk2 (T68), H2AX (S139), and ATM (S1981), leading to p53 response protein p21/Waf1 upregulation and selective growth inhibition against breast cancer MCF-7 (IC50 = 500 nM in 14-d colony formation assay) and 22 lymphoid cell lines (IC50 from 24 nM to 2.2 µM in 7-d viability assay) expressing wt p53, but not BT474 breast cancer or a panel of 25 hematologic cancer cultures with mutant p53 status (IC50 >10 µM). Albeit short in vivo half-life, frequent and high daily oral dosages effectively suppress B-cell lymphoma DoHH2-derived tumor growth in mice (by 41% and 68% in 14 days with 75 mg/kg/12 h or 150 mg/kg/8 h oral dosage, respectively) in vivo. In addition to direct inhibition against Wip1 phosphatase activity, GSK2830371 binding also results in downregulation of cellular Wip1 protein, but not mRNA, level due to ubiquitination-dependent degradation. MG-132 (Cat. Nos. 474790, 474787, 474788, and 474791) effectively prevents GSK2830371-induced Wip1 degradation without interfering with the phosphorylation enhancing effect of GSK2830371 toward Wip1 substrates.
          FormLight yellow powder
          Intert gas (Yes/No) Packaged under inert gas
          Chemical formulaC₂₃H₂₉ClN₄O₂S
          Purity≥97% by HPLC
          SolubilityDMSO (100 mg/ml)
          Storage +2°C to +8°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesGilmartin, A.G., et al. 2014. Nature Chem. Biol. 10, 181.